The associations of three relatively new classes of anti-diabetic medications–glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase 4 inhibitors (DPP-4I), and sodium-glucose cotransporter 2 inhibitors (SGLT-2I) with lung cancer prognosis remain unclear. The gene discussed is DPP4; the disease is lung cancer.